BTMD Q4 2025 Earnings Call Summary

Q4 Revenue: $46.4 million, a decrease of 6.9% year-over-year.
Procedure Revenue: Declined 13% to $31.8 million.
Dietary Supplement Revenue: Grew 16% to $11.7 million, driven by e-commerce growth.
Gross Profit Margin: 68%, down from 71.8%, impacted by a $1.3 million charge from a voluntary recall.
Net Income: $2.6 million, down from $3.5 million; diluted EPS of $0.06 compared to $0.10 in the prior year.
Adjusted EBITDA: Decreased to $11.7 million with a margin of 25.2%, down from 30.3%.
Cash Flow from Operations: $35.2 million; cash and cash equivalents at year-end were $24.1 million.

New Clinic Growth: Reorganized the commercial team, increasing sales personnel from 60 to over 90, focusing on clinic stability and new practitioner recruitment.
Maximizing Existing Clinics: Strengthened relationships with current practitioners and introduced innovative health solutions.
Operational Excellence: Improved internal processes and data analytics to enhance productivity and execution.
Investment Plans: Plans to expand sales personnel to approximately 120 and invest in technology to improve practitioner engagement and retention.

2026 Revenue Forecast: Expected to exceed $190 million, with procedure revenue anticipated to decrease by mid to high single-digit percentages initially, but expected to return to growth in the second half of the year.
Dietary Supplement Revenue: Projected to grow at a mid to high single-digit rate.
Adjusted EBITDA: Expected to exceed $38 million in 2026, despite anticipated increased operating expenses due to investments.

Declining Procedure Revenue: The decrease in procedure revenue is primarily due to higher clinic attrition rates and lower procedure volumes.
Recall Impact: The voluntary recall of hormone pellets has negatively affected gross margins and could influence future revenue and profit.
Attrition Rates: Higher practitioner and clinic attrition rates have been a concern, impacting overall performance and revenue consistency.

FDA Black Box Warning Removal: Management views the FDA's removal of black box warnings for certain hormone replacement therapies as a positive development that could enhance demand.
Recall Feedback: Positive communication with customers regarding the recall; the company is working closely with the FDA to manage the situation.
Future Procedure Volume: Management anticipates a return to growth in procedure volume in the second half of 2026, contingent on stabilizing attrition and enhancing practitioner productivity.

BTMD — biote Corp.